Past, present, and future research in the field of composite tissue allotransplantation.
In September 1998, a surgical team in Lyon, France, performed the first successful hand transplant. After this historic event, in January 1999, the University of Louisville performed the first hand transplant in the United States. These events sparked interest and debate concerning the justification of performing limb allotransplantation. The field of composite tissue allotransplantation (CTA) has made significant advances in the past two decades, yet advancement of the applications of CTA into the clinical arena had been fairly limited to this point. The most inherent controversy in CTA involves the fact that the clinical applications for the most part involve restoration of function and/or structural integrity. These procedures are done essentially for quality-of-life concerns, not life-saving issues. Present concern involves subjecting CTA recipients to a lifetime of postoperative immunosuppressive therapy. We cannot fully understand where we stand at present and in what future directions the field is heading unless we have an understanding of where we have been in composite tissue transplantation. This article reviews the historical aspects of CTA, discusses the present state of CTA, and speculates on potential future applications of CTA.
Kann
B R
BR
Department of Surgery, Division of Surgical Research, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Cooper Hospital/University Medical Center, Camden, NJ, USA.
Furnas
D W
DW
Hewitt
C W
CW
D000818:Animals; D006084:Graft Rejection / Q000517:prevention & control; D063987:Hand Transplantation; D049669:History, 16th Century; D049673:History, 20th Century; D049690:History, Ancient; D049691:History, Medieval; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018644:Roman World; D016378:Tissue Transplantation / Q000266:history / Q000639:trends; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents